A pair of antibodies keeps HIV undetectable by ‘bolting the door and masking the key’
Islatravir plus ulonivirine shows promise for weekly oral HIV treatment
The untapped potential of CD8 cells
New antiretrovirals in the pipeline could be part of twice-yearly HIV treatment
Doravirine/islatravir non-inferior to Biktarvy as first-line treatment
Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens
Antibody from Tanzanian woman suppresses almost all tested HIV variants including resistant viruses in pre-clinical study
Broadly neutralising antibodies plus immune modulator may delay HIV rebound
New long-acting HIV drugs show promising early results
